HER-2 Protein Overexpression clinical trials at UCLA
1 research study open to eligible people
Showing trials for
ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
open to eligible people ages 18 years and up
This is a Phase 1 first-in-human study of ORM-5029 in participants with HER2-expressing advanced solid tumors. The study consists of two parts: a Part 1 Dose Escalation and Part 2 Dose Expansion.
Los Angeles, California and other locations
Last updated: